Role of Selected Genetic Variants in Lung Cancer Risk in African Americans  by Spitz, Margaret R. et al.
391Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013
Introduction: Black/white disparities in lung cancer incidence and 
mortality mandate an evaluation of underlying biological differences. 
We have previously shown higher risks of lung cancer associated 
with prior emphysema in African American compared with white 
patients with lung cancer.
Methods: We therefore evaluated a panel of 1440 inflammatory 
gene variants in a two-phase analysis (discovery and replication), 
added top genome-wide association studies (GWAS) lung can-
cer hits from white populations, and 28 single-nucleotide poly-
morphisms (SNPs) from a published gene panel. The discovery 
set (477 self-designated African Americans cases, 366 controls 
matched on age, ethnicity, and gender) were from Houston, Texas. 
The external replication set (330 cases and 342 controls) was from 
the EXHALE study at Wayne State University.
Results: In discovery, 154 inflammation SNPs were significant 
(p < 0.05) on univariate analysis, as was one of the gene panel SNPs 
(rs308738 in REV1, p = 0.0013), and three GWAS hits, rs16969968 
p = 0.0014 and rs10519203 p = 0.0003 in the 15q locus and 
rs2736100, in the HTERT locus, p = 0.0002. One inflammation SNP, 
rs950286, was successfully replicated with a concordant odds ratio 
of 1.46 (1.14–1.87) in discovery, 1.37 (1.05–1.77) in replication, and 
a combined odds ratio of 1.40 (1.17–1.68). This SNP is intergenic 
between IRF4 and EXOC2 genes. We also constructed and validated 
epidemiologic and extended risk prediction models. The area under 
the curve (AUC) for the epidemiologic discovery model was 0.77 
and 0.80 for the extended model. For the combined datasets, the AUC 
values were 0.75 and 0.76, respectively.
Conclusions: As has been reported for other cancer sites and popu-
lations, incorporating top genetic hits into risk prediction models, 
provides little improvement in model performance and no clinical 
relevance.
Key Words: Inflammation SNPs, Lung cancer, African Americans, 
Risk prediction model.
(J Thorac Oncol. 2013;8: 391-397)
Most family-based, candidate, and genome-wide studies of lung cancer etiology have focused on white or Asian 
populations, yet there is growing recognition of the dispar-
ity between blacks and whites in lung cancer rates, treatment 
options, and outcomes.1–4 African American (AA) men tend 
to smoke fewer cigarettes per day than their white counter-
parts, yet they exhibit higher incidence rates of lung cancer 
(75 per 100,000 versus 64 per 100,000), higher mortality 
rates and their five-year survival rate is 12% versus 15% for 
whites.2 This disproportionate burden of lung cancer in AAs 
requires a concerted approach to examine underlying biologi-
cal differences.
There is strong evidence of the role of an inflammatory 
microenvironment in lung cancer etiology.5 Epidemiological 
studies have shown that lung cancer risk in humans is strongly 
associated with radiographic evidence of parenchymal lung 
destruction (emphysema). It is well established that tobacco-
induced chronic obstructive airways disease is characterized 
by a sustained inflammatory reaction in the airways and lung 
parenchyma. Our data have shown higher risks of lung cancer 
associated with prior emphysema in AA compared with white 
patients with lung cancer.6
Although the role of nicotine dependence genes and 
specifically those in the region of extensive linkage disequi-
librium on chromosome 15q25.1-15q25.1 region have been 
studied in detail in cross ethnic studies that have included AA 
populations,7 other genetic factors associated with lung can-
cer in white patients have been less extensively explored. We 
therefore evaluated a comprehensive panel of inflammatory 
gene variants in risk of lung cancer in a two-phase analysis 
(discovery and replication) and added other selected vari-
ants that have been implicated in lung cancer risk in white 
populations.
We have previously constructed a risk prediction model 
for AAs that included smoking-related variables (smoking 
status, pack-years smoked, age at smoking cessation [former 
smokers], and number of years since smoking cessation [former 
smokers]), self-reported physician diagnoses of emphysema 
or hay fever, and exposures to asbestos or wood dusts.6 In this 
analysis we also added significant genetic variants to the model 
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to see if they improved model performance, and validated the 
epidemiologic and extended models in the external population 
used for replication of the genetic variants.
METHODS
Discovery Set
The discovery set of self-designated AA cases and 
controls was derived from an ongoing multi-racial/ethnic 
lung cancer case-control study,8,9 and were included in the 
construction of the model noted above6 and in a previous 
detailed analysis of a region of extensive linkage disequi-
librium on chromosome 15q25.1.7 Cases were consecutive 
patients at M.D. Anderson Cancer Center and the Lyndon 
Baines Johnson County Hospital recruited from 30 August 
1995 to 11 May 2009 who presented with newly diagnosed, 
histopathologically confirmed and previously untreated 
lung cancer with no age, gender, tumor histology, or disease 
stage restrictions. Medical history, family history of cancer, 
smoking habits, and occupational history were obtained 
through an interviewer-administered risk-factor question-
naire. Institutional review board approval at M.D. Anderson 
Cancer Center was obtained for this study. Case exclusion 
criteria (designed for the parent study that employed func-
tional lymphocyte-based assays) included prior chemother-
apy or radiotherapy within the past 6 months, or recent blood 
transfusion. There were 477 subjects for whom DNA was 
available for genotyping.
Controls were selected to be free of previous cancers 
(excluding non melanoma skin cancer) and were recruited 
(366 controls) from the Kelsey–Seybold Foundation, 
Houston’s largest multidisciplinary physician practice, and 
from local community centers. Controls were frequency 
matched to the cases on age, ethnicity and gender. Never 
smokers were defined as those who had smoked less than 100 
cigarettes in their lifetimes; former smokers were those who 
had quit smoking more than 1 year before diagnosis (cases) 
or interview (controls); and current smokers included those 
who had quit smoking within the past 12 months. The overall 
response rate was approximately 75%. As the genetic analy-
ses were performed on a subset of all the AA cases and con-
trols, the original study design criteria were not met for age 
and gender.
Replication Set
The external replication set (330 cases and 342 con-
trols) was collected as part of the EXHALE study at Wayne 
State University.10 Cases were identified through the popula-
tion-based Metropolitan Detroit Cancer Surveillance System, 
an NCI-funded SEER registry. Rapid case ascertainment was 
used to identify histologically-confirmed cases within several 
months of diagnosis. African-Americans diagnosed with a 
first primary lung cancer from 1 November 2005 through 30 
June 2010 were recruited for the study. Controls were gath-
ered through community-based recruitment and were fre-
quency matched on age (±5 years), sex, and AA ethnicity.10 
Institutional Review Board approval was obtained through 
Wayne State University.
Genotyping
For this analysis in AAs, we evaluated for analysis the 
top 598 SNPs (p < 0.05) selected from interrogating a com-
prehensive panel of 11,737 inflammation pathway SNPs in 
white ever smokers with lung cancer,11 using an Infinium 
iSelect BeadChip (Illumina Inc, San Diego, CA), details of 
which have been previously published. We added an addi-
tional 842 SNPs from inflammation pathways that were 
nominally significant at p < 0.05 in our GWAS data in white 
populations. We also included 28 SNPs from the gene panel 
of Young et al.12 that includes variants in metabolism of 
smoking-derived carcinogens (NAT 2 and CYP2E1), inflam-
matory cytokines (interleukins 1, 8, and 18, tissue necrosis 
factor alpha1 receptor, toll-like receptor 9), smoking addic-
tion (dopamine D2 receptor and Dopamine transporter 1), 
anti-oxidant response to smoking (α1 anti-chymotrypsin and 
extracellular superoxide dismutase), cell cycle control, DNA 
repair and apoptosis (XPD, p73, Bcl-2, FasL,Cerb1, and 
REV1) and integrins implicated in apoptosis.
Finally we added the top hits from Lung GWAS in white 
populations on chromosome 15q25 and chromosome 5p15.13,14 
The total set of SNPs was sent to Illumina (San Diego, CA) for 
custom iSelect Infinium design, out of which 1773 (85%) were 
successfully designed. Genotyping was performed on Illumina’s 
iScan platform according to manufacturer’s standard protocol. 
Genotypes were autocalled using the BeadStudio software. We 
excluded any SNP with a call rate lower than 95% (n = 6) and 
13 SNPs with minor allele frequency (MAF) less than 0.01. 
All replicated SNPs derived from 27 duplicate samples were 
concordant. The final set included 1754 SNPs. Genotyping for 
the replication set was performed using a 5′-nuclease assay 
(TaqMan, Applied Biosystems, Foster City, CA).
Statistical Analyses
Pearson’s χ2 test was used to assess the differences in 
categorical variables and t-tests were used for continuous 
variables in both discovery and replication data sets. All tests 
were two sided. To assess case-control associations of SNP 
genotypes with lung cancer risk we used unconditional logis-
tic regression, implemented using SAS/Genetics version 9.2 
(SAS Institute, Cary, NC), with and without adjustment for 
age, sex, pack-year, and family history of cancer in first degree 
relatives. Single-SNP association tests were carried out using 
PLINK 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/).15
We applied the Bayesian false discovery probability 
test16 to evaluate the chance of obtaining a false-positive 
association. This approach calculates the probability of 
declaring no association given the data and a specified prior on 
the presence of an association, and has a noteworthy threshold 
that is defined in terms of the costs of false discovery and 
non-discovery. Four levels of prior probability of 0.01, 0.03, 
0.05, and 0.07 and prior odds ratios of 1.2, 1.3, 1.4, and 1.5 
were tested and selected levels of noteworthiness for Bayesian 
false discovery probability test were set at 0.8, that is false 
nondiscovery rate is four times as costly as false discovery. 
Since we are employing a candidate pathway rather than a 
hypothesis generating approach, we believe that an odds ratio 
(OR) of 1.5 is reasonable. We used a conservative prior of 
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0.05 to determine that the association is unlikely to represent 
a false-positive result.
In stratified analyses, we used logistic regression to 
examine associations of selected SNPs with lung cancer case-
control status for subgroups of subjects defined by gender, 
packyears, histology, history of emphysema or family history 
of lung cancer, comparing each sub-group of cases against 
controls within that subgroup.
We incorporated exposure variables (age, sex, cigarette 
pack years, prior self-reported history of emphysema as diag-
nosed by a physician, hay fever, and asbestos and wood dust 
exposures) that were components of our published risk pre-
diction model for AAs6 in a logistic regression model.Wood 
dust exposure fell out of the final model. We also performed 
a backward selection logistic regression analysis in which we 
allowed significant univariate SNPs to remain in the model 
according to the strength of association, provided they showed 
association with disease (p < 0.05). SNPs were retained for 
analysis if they continued to show association (p < 0.10) given 
other SNPs in the model. Tests for SNP by SNP interaction 
were evaluated using logistic regression analysis.
For risk model construction and validation, we used 
the discovery and replication sets separately and combined to 
explore both epidemiologic and extended models with genetic 
variables added. For each risk model, we calculated specific-
ity and sensitivity of the resulting logistic regression model 
by constructing receiver operator characteristic (ROC) curves 
and calculating the area under the curve (AUC) statistic to 
estimate the model’s ability to discriminate between patients 
and controls for the two populations separately and combined. 
Approximate 95% confidence intervals for the AUC were cal-
culated assuming a binegative exponential distribution using 
SAS statistical software. An AUC of 0.5 indicates chance pre-
diction (equivalent to a coin toss), whereas a statistic of 0.7 
or higher indicates good discrimination. We performed pair-
wise comparisons of AUCs of the baseline multiple logistic 
model, and the expanded model including genetic data using 
a contrast matrix to evaluate differences of the areas under 
the empirical ROC curves.17 For validation of the model 
we included all demographic variables and SNPs that were 
selected in the final model from the discovery set. We used the 
estimates derived from the discovery set to fit this replication 
set and calculated the AUC, positive predictive value (PPV) 
and misclassification rate.
RESULTS
Discovery Phase
In the discovery set, the cases were significantly more 
likely to be male and older than the controls, reflecting incom-
plete matching (Table 1) because the genetic analyses were 
performed on a subset of all the available cases and controls. 
The replication set was well matched on gender and age. In 
both groups, the cases were significantly more likely to be 
ever smokers and report heavier smoking histories than their 
respective controls (p < 0.001). The mean number of cigarettes 
smoked per day was 20.7 for the discovery cases versus 19.3 
for the replication cases. In our parallel case-control study 
in whites, the average number of cigarettes per day was 28.1 
in cases compared with 26.4 in white controls (p ≤ 0.001).11 
Exposure to asbestos and self-reported emphysema differed 
significantly between case and controls in both data sets. 
Adenocarcinoma was the most common histological diagno-
sis followed by squamous cell cancer. We performed pair-wise 
analysis for the significant SNPs in the model, and no interac-
tions were found to be statistically significant at p = 0.05 level.
There were 154 inflammation pathway SNPs that were 
statistically significant (p < 0.05) on univariate analysis. In 
addition, one of the 28 SNPs from the Young et al.12 panel 
of SNPs was significant (rs308738 in REV1 on 2q11.1-q11.2, 
p = 0.0013), as were three of the GWAS top hits, rs16969968 
p = 0.0014 and rs10519203 p = 0.0003 in the 15q locus 
(r-squared = 0.136), and rs2736100, the HTERT locus on chr 
5 p = 0.0002, data not shown.
Replication
For replication, we selected the top inflammation hits 
(p < 0.01; n = 27) from the discovery analysis and the top 
inflammation pathway SNPs from our discovery analysis of 
inflammation hits (p < 0.05, n = 33) in white ever smokers.11 
Four inflammation SNPs were statistically significant in the 
replication analysis (Table 2), but only one was successfully 
replicated with a concordant odds ratio and after controlling 
for false discovery. rs950286 was associated with significantly 
elevated risks of 1.46 (1.14–1.87) in the discovery set and 1.37 
(1.05–1.77) in the replication set. The combined risk estimate 
was 1.40 (1.17–1.68), p = 0.002. This SNP was significant in 
ever but not never smokers and in those with adenocarcinoma, 
but not squamous cell cancer. There were no differences by 
gender or family history. The risk estimate was higher in those 
with self-reported emphysema than those without, (2.87 ver-
sus 1.47), but the former was not significant (p = 0.19, data 
not shown). In addition, rs7124327 was of borderline signifi-
cance in the discovery set (OR = 0.72 [0.52–1.01]), was not 
significant in the replication set (OR = 0.85 [0.60–1.20]), but 
reached statistical significance in the combined data set (OR = 
0.77 [0.61–0.98], p = 0.0331).
In multiple logistic regression analysis of the combined 
population groups (Table 3), pack years (OR = 1.03 [1.02–
1.03], p < 0.0001); asbestos exposure (OR = 1.64 [1.24–2.16], 
p = 0.005); emphysema (OR = 3.46 [2.18–5.48], p < 0.0001); 
prior hay fever (OR = 0.66 [0.49–0.89], p = 0.0072); and fam-
ily history of cancer (OR = 1.17 [1.05–1.31], p = 0.004) were 
all statistically significant. Next we added the significant and 
borderline significant inflammation SNPs (rs950286 and 
rs7124327), together with the chromsome 15 and chromosome 
5 SNPs and Rev1 to the logistic regression model (Table 3). With 
the exception of one SNP that was not significant, (rs3087386, 
p = 0.3996), all others remained statistically significant.
For the risk prediction models, (Table 4) we computed 
the area under the curve values (C statistic) for a baseline 
epidemiologic model incorporating variables that were 
available in both data sets (age, gender, pack years, asbestos 
exposure, self-reported emphysema and hay fever, and family 
history of cancer in a first degree relative). The replication 
data lacked information on prior hay fever and we used the 
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available variable of self-reported allergies. The AUC for 
the discovery set was 0.77 (0.74–0.81). When we added the 
SNPs to the epidemiologic model, the AUC increased to 
0.80 (0.77–0.84), p = 0.0014. In the replication set, the AUC 
for the extended model was 0.68, with a positive predictive 
value of 68%. Using only the epidemiologic data, the PPV 
was 72%. If we conservatively removed the variable of hay 
fever/allergies and rs3087386, that was not significant in 
multivariate analysis, the PPV for the validation set was 
71%, and the misclassification rate was 36%, data not shown. 
Adding the genetic data to the replication epidemiologic 
model actually reduced model performance (AUC = 0.67). 
Combining the data for both sets yielded AUC values of 
0.75 (0.72–0.77) and 0.76 (0.73–0.79) for the baseline and 
extended models respectively (Table 4). We used the Hosmer–
Lemeshow goodness-of-fit test to assess model calibration for 
the combined data. The resultant test statistic was 6.64 with 
p = 0.5755 indicating that the fitted model was an adequate 
model We also performed net reclassification index analysis.18 
The net reclassification index for the expanded model was 
0.27 (0.16–0.38) p < 0.0001. 13% of the cases and 14% of 
the controls were correctly reclassified using the extended 
model, an improvement in model performance that could be 
considered only as modest.
TABLE 1.  Distribution of Select Variables in Discovery and Replication Populations
Discovery Replication
Cases Controls p Value* Cases Controls p Value*
Sex
 Male 255 (53.46) 155 (42.35) 167 (50.61) 175 (51.17)
 Female 222 (46.54) 211 (57.65) 0.0014 163 ( 49.39) 167 (48.83) 0.8839
Age
 Mean (SD) 62.4 (10.3) 55.4 (11.3) <0.001 62.5 (10.3) 62.7 (10.3) 0.8281
 Range 34–89 22–87 36–89 38–87
Smoking status
 Never 55 (11.53) 95 (25.96) 20 (6.06) 104 (30.41)
 Ever 422 (88.47) 271 (74.04) <0.001 310 (93.94) 238 (69.59) <0.001
No. of cigarettes/day
 Mean (SD) 20.7 (12.0) 16.3 (11.2) <0.001 19.3 (10.2) 16.2 (11.6) <0.001
Years smoked
 Mean (SD) 37.9 (12.2) 28.9 (12.8) <0.001 39.7 (11.3) 33.5 (11.8) <0.001
 Range 3–68 1–58 3–78 2–64
Pack-years
 Mean (SD) 40.2 (27.4) 24.8 (21.7) <0.001 39.3 (25.7) 27.7 (20.8) <0.001
 Range 0.3–200 0.2–147 1–174 1–138
Asbestos
 Yes 160 (34.26) 81 (22.38) 0.0002 100 (30.49) 65 (19.06) 0.0006
 No 307 (65.74) 281 (77.62) 228 (69.51) 276 (80.94)
Emphysema
 Yes 70 (14.77) 10 (2.73) <0.001 73 (22.12) 18 (5.28) <0.001
 No 404 (85.23) 356 (97.27) 257 (77.88) 323 (94.72)
Hayfever/allergy
 Yes 48 (10.17) 74 (20.22) <0.001 81 (24.62) 81 (23.68) 0.7770
 No 424 (89.83) 292 (79.78) 248 (75.38) 261 (76.32)
Family history of cancer
 0 152 (22.70) 167 (45.88) 0.0004 137 (41.52) 163 (47.66) 0.1091
 1+ 299 (66.30) 197 (54.12) 193 (58.48) 179 (52.34)
Histology** N (%) N (%)
Adeno 212 (44.4) 117 (35.5)
Squamous 133 (27.9) 86 (26.1)
NSCLC 94 (19.8) 74 (15.5)
Small Cell 24 (5.0) 22 (4.6)
Other 14 (2.9) 31 (9.4)
*p Value from two-sided χ2 test for categorical variables and Student’s t-test for continuous variables.
**p Value between two case groups = 0.0004.
NSCLC, non–small-cell lung cancer.
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DISCUSSION
In this two-phase analysis of SNPs in the inflammation 
pathway and top lung cancer hits in AAs, we replicated one 
SNP in an inflammation gene, a suggestive association with 
another; and REV1 from the Young et al.12 gene set list (in 
the Discovery set only) and three GWAS hits from studies on 
white population. Our data also showed that the epidemiologic 
model constructed with the discovery data, fit the replication 
data fairly well. However, adding these SNPs to the epidemio-
logic risk prediction model did not substantively improve the 
model performance.
The replicated inflammation SNP, rs950286, was sig-
nificant in ever but not never smokers and in patients with 
the histologic diagnosis of adenocarcinoma. . In white ever 
smokers from our GWAS, the OR for this SNP was 1.25, p = 
0.022. This OR is concordant with the data reported here 
for AAs. This SNP is intergenic between IRF4 and EXOC2 
genes. Interferon regulatory factor 4 is a protein encoded 
by IRF4, also known as MUM1. MUM1/IRF4 protein is a 
member of the interferon regulatory factor (IRF) family of 
transcriptional factors that are downstream regulators of 
TABLE 2.  Risk Estimates for Selected SNPs (Additive Model)
SNP
Discovery population Replication population
Case (n = 477) Control (n = 366) OR (95% CI) p Value* Case (n = 330) Control (n = 342) OR (95% CI) p Value*
rs6994744
CC 281 (58.91) 252 (68.85) C/C 219 (66.57) 192 (56.47)
AC 165 (34.59) 100 (27.32) A/C 94 (28.57) 134 (39.41)
AA 31 (6.50) 14 (3.83) 1.45 (1.14–1.84) 0.0023 A/A 16 (4.86) 14 (4.12) 0.76 (0.58–0.98) 0.0373
rs7943570
AA 112 (23.48) 118 (32.24) T/T 100 (30.58) 87 (25.66)
GA 242 (50.73) 173 (47.27) C/T 161 (49.24) 152 (44.84)
GG 123 (25.79) 75 (20.49) 1.32 (1.09–1.61) 0.0046 C/C 66 (20.18) 100 (29.50) 0.76 (0.62–0.94) 0.0118
rs950286a
GG 279 (58.49) 253 (69.13) G/G 186 (56.71) 224 (65.50)
AG 177 (37.11) 101 (27.60) A/G 122 (37.20) 104 (30.41)
AA 21 (4.40) 12 (3.28) 1.46 (1.14–1.87) 0.0029 A/A 20 (6.10) 14 (4.09) 1.37 (1.05–1.77) 0.0183
rs7124327b
CC 405 (84.91) 296 (80.87) C/C 270 (81.82) 271 (79.24)
AC 70 (14.68) 63 (17.21) A/C 57 (17.27) 66 (19.30)
AA 2 (0.42) 7 (1.91) 0.72 (0.52–1.01) 0.0539 A/A 3 (0.91) 5 (1.46) 0.85 (0.60–1.20) 0.3497
aBFDP for OR = 1.5 and priors of 0.03 and 0.05 ≤0.70.
bBFDP for OR = 1.5 and priors of 0.03 and 0.05 >0.70.
*p Value from the two-sided χ2 test.
CI, confidence intervals; OR, odds ratio.
TABLE 3.  Logistic Regression Analysis: Combined Data
Epidemiologic model Extended model with SNPs
Variable OR (95%CI) p Value* OR (95%CI) p Value*
Age 1.02 (1.01–1.03) <0.0001 1.02 (1.01–1.04) <0.0001
Sex 0.72 (0.56–0.93) 0.013 0.72 (0.55–0.94) 0.0146
Packyears 1.03 (1.02–1.03) <0.0001 1.03 (1.02–1.03) <0.0001
Asbestos 1.64 (1.24–2.16) 0.0005 1.63 (1.23–2.15) 0.0008
Emphysema 3.46 (2.18–5.48) <0.0001 3.71 (2.32–5.93) <0.0001
Hay fever 0.66 (0.49–0.89) 0.0072 0.68 (0.50–0.93) 0.0146
FH cancer 1.17 (1.05–1.31) 0.004 1.16 (1.04–1.30) 0.0076
rs950286 1.46 (1.18–1.81) 0.0005
rs7124327 0.70 (0.52–0.93) 0.0156
rs2736100 1.24 (1.05–1.48) 0.0133
rs16969968 1.58 (1.10–2.28) 0.013
rs3087386 1.08 (0.90–1.31) 0.3996
rs10519203 1.22 (1.00–1.48) 0.0471
*p Value from wald test.
CI, confidence intervals; OR, odds ratio.
TABLE 4.  Risk Prediction Model Performance
Model AUC (95% CI) p Value
Discovery set
 Epidemiologic 0.77 (0.74–0.81) 0.0014
 Extended 0.80 (0.77–0.84)
Validation data
 Epidemiologic 0.68 (0.64–0.72)
 Extended 0.67 (0.62–0.71) 0.0844
Combined datasets
 Epidemiologic 0.75 (0.72–0.77) 0.0185
 Extended 0.76 (0.73–0.79)
*p Value comparing two AUCs calculated from Wald test.
AUC, area under the curve; CI, confidence intervals.
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interferon signaling.19 It is expressed in cells of the immune 
system, where it transduces signals from various receptors 
to activate or repress gene expression and regulates the dif-
ferentiation of mature B cells into antibody-secreting plasma 
cells.20 Exocyst complex component 2 is a component of the 
exocyst complex, a multiple protein complex essential for 
targeting exocytic vesicles to specific docking sites on the 
plasma membrane.
There was also a suggestive association with rs7124327, 
on CD44 that encodes a cell-surface glycoprotein involved 
in cell-cell interactions, cell adhesion and migration. It is a 
receptor for hyaluronic acid and can also interact with other 
ligands, including collagens, and matrix metalloproteinases. 
Leung et al.21 have shown tumorigenicity of CD44+ cells using 
both in vitro and in vivo approaches. They also demonstrated 
tumor cell expression of CD44 in about half of non small cell 
lung tumors. High CD44 expression was a negative prognostic 
marker in patients with resected non–small-cell lung cancer, 
particularly those with adenocarcinoma histology, and was 
independent of tumor stage.22 This gene has not been previ-
ously implicated in lung cancer risk. However, we noted that 
this SNP was also significantly associated with risk (and in 
the same direction) in our white ever smokers (OR = 0.86, 
 p = 0.04).11
The association with two SNPs in the chromosome 15q 
locus (rs16969968 and rs1051730) has been reported previ-
ously in both white GWAS populations and in AA studies, 
including our own.7,23,24 rs16969968 has been robustly associ-
ated with smoking intensity (p < 0.01) in each of three popula-
tions (European ancestry, Asian, and AA with an odds ratio of 
1.33, 95% confidence intervals = 1.25–1.42, p = 1.1 × 10−17 in 
meta-analysis across all population samples.23 rs16969968 and 
rs1051730 are highly correlated (r2 = 1) in European ancestry 
and Asian populations, but display only modest correlation in 
AAs (r 2= 0.40; HapMap 3 Release 2). This variant is the most 
strongly associated polymorphism across all three populations 
and causes an amino acid change in the nicotinic receptor α5 
subunit that alters function of its receptor.25 Chen et al.23 main-
tain that rs16969968, rather than rs1051730, is most likely to 
be driving the association with smoking intensity.
Finally, rs2736100, a G/T variation in the TERT gene 
(intronic) on human chromosome 5 was statistically signifi-
cant in our data. A number of well-designed GWAS and meta-
analysis have implicated variants at the 5p15.33 locus in cancer 
risk at several different sites, including lung cancer in both 
whites and Asians.26 To our knowledge this is the first demon-
stration that the SNP is also important in AAs. The strongest 
risk association was noted for adenocarcinoma in all genetic 
models. Recently, mean relative telomere length was associ-
ated with four genetic variants of the hTERT gene, including 
rs2736100.27 TERT gene amplification is responsible for TERT 
mRNA overexpression in a majority of adenocarcinomas.28 
TERT is active in rapidly dividing cells of the immune system 
and is said to be related to endothelial nitric oxide synthase 
control,29 also involved in the immune response.
The only significant SNP from the Young et al.12 panel 
was rs3087386 in REV1 at chromosome 2q11.1-q11.2. The 
Rev1 proteins contain a BRCA1 C Terminus (BRCT) domain, 
important in protein-protein interactions. A suggested role 
for the human Rev1-like protein is as a scaffold that recruits 
DNA polymerases involved in translesion synthesis triggered 
by several types of damaged bases, including those caused 
by benzo(a)pyrene. In preclinical models, lowering of REV1 
transcripts was associated with a significant decrease in the 
multiplicity of carcinogen-induced lung tumors and complete 
abolishment of tumor formation in 27% of the carcinogen-
exposed mice.30 These data support the central role of the 
translesion synthesis pathway in the development of lung 
cancer. Sakiyama31 reported that ORs in homozygotes for the 
REV1-257Ser allele were higher in heavy-smoker squamous 
cell cases than light-smoker squamous cell cases.
Our previously published risk prediction model for 
African Americans6 on a slightly larger data set than used for 
this analysis, exhibited good discrimination (AUC = 0.75). 
Our discovery data yielded a similar AUC (0.77) and we were 
able to demonstrate moderate discrimination (68%) for the 
external validation set, which is an improvement over our par-
allel model for white subjects. We demonstrated an improve-
ment with addition of the significant SNPs in the discovery set, 
and combined data sets, but not for the replication data. This 
may partly be explained by the fact that two SNPs exhibited 
ORs in discordant directions in the replication set, that could 
be attributed to small sample sizes and allele frequencies in 
controls that differed between Detroit and Texas. Although the 
marginal increase in the extended model was statistically sig-
nificant, it is not likely to be of any clinical relevance.
Other limitations of this study include differences in 
sampling strategies for the two populations. Although the 
discovery set was hospital-based and the replication set was 
population-based, there were no significant differences in 
stage between the two case groups. The percentages of local/
regional disease were 55 and 59%, respectively. Likewise 
the distribution of distant disease was 45 and 41%, respec-
tively, p = 0.25. We performed stratified analyses to evaluate 
the SNPs in the model with gender and smoking status (ever/
never). However, none of those were found to be statistically 
significant (p > 0.05). Unfortunately we lacked information 
on the severity of emphysema and were unable to evaluate 
this phenotype in greater detail. Another limitation could be 
the method of selection of inflammation SNPs that was based 
on the CEPH database and included only those with a MAF 
greater than 5%. Due to differences in population structure, 
the allele frequencies of the selected SNPs may differ in 
AAs, and other ethnic-specific SNPs may have been missed. 
A subset of these cases and controls from both the discovery 
and replication sets was included in an admixture mapping 
study.10 The mean proportion of African ancestry in cases and 
controls combined was 80.7% in the replication population 
and 78.4% in the Texas participants. This small difference is 
unlikely to drive any of the reported associations. The aver-
age percent information extracted by the marker panel, rep-
resenting a measure of the overall coverage of the panel was 
74.1%. In addition, there were no significant differences in 
allelic distribution for our SNPs of interest in the two control 
groups, further suggesting that the populations are similar in 
ancestry.
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In summary, this analysis demonstrates, as has been 
reported for other cancer sites and different populations, that 
incorporating top genetic hits into epidemiologic risk predic-
tion models, has not yet proven to be of any clinical or prog-
nostic value in these AA lung cancer cases.
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